9 results about "Atrial flutter" patented technology

The present invention provides methods of treating or preventing atrial fibrillation, atrial flutter, or a combination thereof comprising intravenously administering sotalol hydrochloride to a subject in need thereof. Embodiments of the present invention further provide novel methods of intravenously administering sotalol hydrochloride for example in pediatric patients. The present invention provides a novel intravenous, prophylactic, antiarrhythmic method of sotalol administration.

The invention involves a novel method of converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL by administering at least a loading dose of dofetilide intravenously, or if that fails cardioversion and a maintenance infusion followed by a switch to chronic oral dosing.

The present disclosure relates to compositions and methods, including prodrugs of (S)-sec-butyl 2-(3-(4-(2- (diethylamino)ethoxy)-3,5-diiodobenzoyl)benzofuran-2-yl) acetate that find use in the treatment of diseases and disorders, such as therapies for cardiovascular disease, including cardiac arrhythmias, including, without limitations, atrial fibrillation, paroxysmal atrial fibrillation, atrial flutter, ventricular arrhythmias, or ventricular fibrillation.

A photoplethysmography or PPG signal processing device configured to detect atrial flutter, includes a processor and memory including computer program code The processor and memory are configured to cause the PPG signal processing device toobtain (101) at least one PPG signal (200) for a human or animal;detect (102) heartbeats (201, 202, 203, 204, 205, . . . ) in the at least one PPG signal (200); anddetermine (103) interbeat intervals (301, 302, 303, 304, . . . ) for pairs of consecutive heartbeats (201-202, 202-203, 203-204, 204-205, . . . ) in the at least one PPG signal (200).The processor and memory cause the PPG signal processing device to detect (104) interbeat interval baselines, each interbeat interval baseline (302-304) corresponding to a plurality of consecutive interbeat intervals (302, 303, 304) that are constant within a predefined tolerance value;determine (105) respective average interbeat interval values (401, 402, . . . ) for the interbeat interval baselines (302-304); anddetect (110) a relationship between the average interbeat interval values (401, 402, . . . ; 501, 502, . . . ).

The present invention involves novel safe dosage regimens comprising the administration of a loading and maintenance dose of dofetilide iv, followed by oral dosing of dofetilide. Methods include (a) reducing the risk of developing atrial fibrillation (AF) and / or atrial flutter (AFL) post coronary bypass surgery (CABS); (b) terminating arrhythmic storm in patients following implementation of an implantable defibrillator by administrating loading and maintenance infusions of dofetilide intravenously followed by oral dosing; and, (c) converting atrial fibrillation (AF) or atrial flutter (AFL) in a patient presenting with highly symptomatic AF or AFL.

The invention relates to an atrial arrhythmia recognition method and system based on a space-time diagram neural network and atrial signal source reconstruction and a storage medium. According to the method, source decoupling of ventricular and atrial activities is achieved through a signal processing architecture combining independent component analysis and variational mode decomposition; the atrial signal extraction distortion under wide QRS wave group and noise interference is fundamentally avoided; meanwhile, a multi-modal feature system fusing time domain dynamics, frequency domain morphology and spatial synchronism is constructed, and a space-time diagram convolutional network constructed based on lead physical and physiological topology is matched, so that the space-time dependency relationship of the multi-lead electrocardiosignals is effectively captured. In addition, the introduced attention mechanism provides a visual decision basis, and the accuracy and interpretability of atrial fibrillation and atrial flutter identification in complex pathological scenes with conduction block and the like are remarkably improved.

In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy and having atrial fibrillation and / or flutter by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.